-$0.45 EPS Expected for Entellus Medical Inc (ENTL) This Quarter
Equities research analysts expect Entellus Medical Inc (NASDAQ:ENTL) to post earnings per share of ($0.45) for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Entellus Medical’s earnings. The highest EPS estimate is ($0.44) and the lowest is ($0.45). Entellus Medical posted earnings per share of ($0.39) in the same quarter last year, which suggests a negative year-over-year growth rate of 15.4%. The company is scheduled to issue its next quarterly earnings report on Tuesday, February 20th.
According to Zacks, analysts expect that Entellus Medical will report full year earnings of ($1.33) per share for the current fiscal year. For the next year, analysts anticipate that the company will post earnings of ($1.42) per share, with EPS estimates ranging from ($1.64) to ($1.15). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that cover Entellus Medical.
Entellus Medical (NASDAQ:ENTL) last released its earnings results on Wednesday, November 1st. The medical technology company reported ($0.49) EPS for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.02. Entellus Medical had a negative net margin of 31.24% and a negative return on equity of 47.37%.
Shares of Entellus Medical (NASDAQ ENTL) opened at $24.09 on Thursday. The company has a current ratio of 1.92, a quick ratio of 1.71 and a debt-to-equity ratio of 0.32. Entellus Medical has a fifty-two week low of $11.47 and a fifty-two week high of $25.58. The company has a market cap of $618.89, a price-to-earnings ratio of -18.67 and a beta of 0.02.
In related news, VP Kevin L. Mensink sold 2,500 shares of the business’s stock in a transaction on Friday, October 20th. The shares were sold at an average price of $19.00, for a total value of $47,500.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Brian E. Farley sold 101,319 shares of the business’s stock in a transaction on Thursday, December 7th. The shares were sold at an average price of $23.85, for a total transaction of $2,416,458.15. The disclosure for this sale can be found here. Insiders sold a total of 111,442 shares of company stock valued at $2,647,158 in the last three months. 7.70% of the stock is owned by company insiders.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of New York Mellon Corp lifted its position in Entellus Medical by 29.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 40,783 shares of the medical technology company’s stock valued at $675,000 after acquiring an additional 9,270 shares in the last quarter. California State Teachers Retirement System lifted its position in Entellus Medical by 26.4% in the 2nd quarter. California State Teachers Retirement System now owns 21,517 shares of the medical technology company’s stock valued at $356,000 after acquiring an additional 4,500 shares in the last quarter. Archon Capital Management LLC lifted its position in Entellus Medical by 34.3% in the 2nd quarter. Archon Capital Management LLC now owns 478,820 shares of the medical technology company’s stock valued at $7,929,000 after acquiring an additional 122,171 shares in the last quarter. Wasatch Advisors Inc. lifted its position in Entellus Medical by 6.7% in the 2nd quarter. Wasatch Advisors Inc. now owns 231,656 shares of the medical technology company’s stock valued at $3,836,000 after acquiring an additional 14,462 shares in the last quarter. Finally, Grandeur Peak Global Advisors LLC lifted its position in Entellus Medical by 3.5% in the 2nd quarter. Grandeur Peak Global Advisors LLC now owns 219,971 shares of the medical technology company’s stock valued at $3,643,000 after acquiring an additional 7,480 shares in the last quarter. 78.24% of the stock is currently owned by institutional investors and hedge funds.
About Entellus Medical
Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Entellus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical and related companies with MarketBeat.com's FREE daily email newsletter.